KRSA · Korsana Biosciences, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $1.9M | $2.07M | $2M | $0 | $297K | $3.94M | $2.3M | $4.51M | — | |
| $1.6M | $959K | $286K | $1.52M | $5.98M | $37.64M | $56.41M | $95.14M | $87.72M | |
| $7.13M | $6.09M | $5.34M | $8.13M | $12.86M | $20.62M | $28.82M | $34.4M | $27.54M | |
| — | — | — | $0 | $65K | $472K | $2.3M | $2.7M | $1.53M | |
| — | — | — | -$565K | -$1.33M | — | — | — | — | |
| $1.77M | $7.05M | $5.63M | $12.95M | $18.84M | $59.14M | $83.56M | $129.54M | $115.25M | |
| -$6.82M | -$4.97M | -$3.63M | -$12.95M | -$18.54M | -$55.2M | -$81.27M | -$125.04M | -$115.25M | |
| — | -239.78% | -181.4% | — | -6242.42% | -1400.18% | -3539.42% | -2774.28% | — | |
| — | — | — | -$12.95M | -$18.48M | -$54.72M | -$78.97M | -$122.34M | -$113.72M | |
| $117K | $1.45M | $571K | $358K | $294K | -$16K | $588K | — | — | |
| — | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$122.41M | -$122.41M | -$115.25M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$6.71M | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$77.8M | -$123.01M | -$115.25M | |
| — | -170.11% | -152.85% | — | -14841.08% | -1310.17% | -3388.59% | -2729.27% | — | |
| USD/shares | -$11.27 | -$7.77 | -$8.47 | -$15.75 | -$141.96 | -$184.80 | — | — | — |
| USD/shares | -$11.27 | -$7.77 | -$8.47 | -$15.75 | -$141.96 | -$184.80 | — | — | — |
| shares | — | 454.43K | 359.71K | 334K | 310.43K | 279.6K | 217.16K | 195.57K | 195.5714 |
| shares | — | 454.43K | 359.71K | 334K | 310.43K | 279.6K | 217.16K | 195.57K | 195.5714 |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 246 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| License Agreement | $1,000,000 | $1,750,000 | $0 |
| Purchase Agreement | $800,000 | $0 | — |
| Option Agreement | $274,000 | $250,000 | — |
| License | — | — | $0 |